Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis Acquires China Rights to Alphamab's PD-L1 for Hepatitis B

publication date: Jan 14, 2019

Ascletis Pharma of Hangzhou acquired China rights to a Suzhou Alphamab anti-PD-L1 candidate for hepatitis B and other viral disease indications. Ascletis will make an upfront payment, and Alphamab will be eligible to receive payments for development and commercial milestones plus royalties ranging from the mid-teens to around twenty percent. Alphamab will manufacture the candidate. Ascletis will be eligible to share in future upfront, milestone and royalty if ASC22 (KN035) is approved to treat viral diseases outside of Greater China. More details....

Stock Symbol: (HK; 1672)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.